NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 12.89 Million USD | -16.58% |
| 2022 | 15.46 Million USD | 6.58% |
| 2021 | 14.5 Million USD | 17.09% |
| 2020 | 12.39 Million USD | -13.12% |
| 2019 | 14.26 Million USD | -24.45% |
| 2018 | 18.87 Million USD | -17.05% |
| 2017 | 22.75 Million USD | 11.47% |
| 2016 | 20.41 Million USD | -15.41% |
| 2015 | 24.13 Million USD | 38.34% |
| 2014 | 17.44 Million USD | -7.21% |
| 2013 | 18.8 Million USD | 23.24% |
| 2012 | 15.25 Million USD | -0.55% |
| 2011 | 15.34 Million USD | 7.5% |
| 2010 | 14.27 Million USD | 10.24% |
| 2009 | 12.94 Million USD | -15.02% |
| 2008 | 15.23 Million USD | 29.2% |
| 2007 | 11.78 Million USD | 67.01% |
| 2006 | 7.05 Million USD | 97.79% |
| 2005 | 3.56 Million USD | 227.28% |
| 2004 | -2.8 Million USD | -394.23% |
| 2003 | 953 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.36 Million USD | 28.78% |
| 2024 Q2 | 2.64 Million USD | -21.4% |
| 2023 Q1 | 3.67 Million USD | -17.42% |
| 2023 FY | 12.89 Million USD | -16.58% |
| 2023 Q2 | 3.66 Million USD | -0.25% |
| 2023 Q3 | 2.95 Million USD | -19.31% |
| 2023 Q4 | 2.61 Million USD | -11.54% |
| 2022 Q4 | 4.44 Million USD | 56.92% |
| 2022 Q1 | 3.89 Million USD | -15.65% |
| 2022 FY | 15.46 Million USD | 6.58% |
| 2022 Q2 | 3.7 Million USD | -5.03% |
| 2022 Q3 | 2.83 Million USD | -23.5% |
| 2021 Q4 | 4.62 Million USD | 27.09% |
| 2021 FY | 14.5 Million USD | 17.09% |
| 2021 Q1 | 2.87 Million USD | 1.38% |
| 2021 Q2 | 3.37 Million USD | 17.62% |
| 2021 Q3 | 3.63 Million USD | 7.64% |
| 2020 Q4 | 2.83 Million USD | -23.35% |
| 2020 Q1 | 2.84 Million USD | -15.02% |
| 2020 Q2 | 3.01 Million USD | 5.94% |
| 2020 FY | 12.39 Million USD | -13.12% |
| 2020 Q3 | 3.69 Million USD | 22.59% |
| 2019 Q2 | 2.76 Million USD | -47.04% |
| 2019 Q4 | 3.34 Million USD | 14.46% |
| 2019 FY | 14.26 Million USD | -24.45% |
| 2019 Q1 | 5.22 Million USD | 8.88% |
| 2019 Q3 | 2.92 Million USD | 5.82% |
| 2018 Q2 | 4.39 Million USD | -13.15% |
| 2018 FY | 18.87 Million USD | -17.05% |
| 2018 Q3 | 4.61 Million USD | 5.03% |
| 2018 Q4 | 4.79 Million USD | 3.81% |
| 2018 Q1 | 5.06 Million USD | 2.37% |
| 2017 Q3 | 5.73 Million USD | 10.77% |
| 2017 Q2 | 5.18 Million USD | -24.8% |
| 2017 Q1 | 6.89 Million USD | 27.38% |
| 2017 FY | 22.75 Million USD | 11.47% |
| 2017 Q4 | 4.94 Million USD | -13.8% |
| 2016 Q1 | 5.73 Million USD | -20.28% |
| 2016 Q4 | 5.4 Million USD | 10.73% |
| 2016 FY | 20.41 Million USD | -15.41% |
| 2016 Q3 | 4.88 Million USD | 11.3% |
| 2016 Q2 | 4.38 Million USD | -23.43% |
| 2015 Q2 | 5.61 Million USD | 11.15% |
| 2015 Q4 | 7.19 Million USD | 14.51% |
| 2015 Q3 | 6.27 Million USD | 11.85% |
| 2015 FY | 24.13 Million USD | 38.34% |
| 2015 Q1 | 5.05 Million USD | -0.86% |
| 2014 Q4 | 5.09 Million USD | 20.65% |
| 2014 Q1 | 4.23 Million USD | -20.02% |
| 2014 FY | 17.44 Million USD | -7.21% |
| 2014 Q2 | 3.89 Million USD | -8.14% |
| 2014 Q3 | 4.22 Million USD | 8.53% |
| 2013 Q4 | 5.29 Million USD | 31.15% |
| 2013 Q2 | 4.98 Million USD | 11.08% |
| 2013 Q3 | 4.03 Million USD | -18.95% |
| 2013 FY | 18.8 Million USD | 23.24% |
| 2013 Q1 | 4.48 Million USD | 13.4% |
| 2012 Q4 | 3.95 Million USD | 5.52% |
| 2012 FY | 15.25 Million USD | -0.55% |
| 2012 Q1 | 3.8 Million USD | 2.89% |
| 2012 Q2 | 3.74 Million USD | -1.55% |
| 2012 Q3 | 3.74 Million USD | 0.05% |
| 2011 Q4 | 3.69 Million USD | 18.53% |
| 2011 Q2 | 4.08 Million USD | -7.85% |
| 2011 Q1 | 4.43 Million USD | 43.25% |
| 2011 FY | 15.34 Million USD | 7.5% |
| 2011 Q3 | 3.12 Million USD | -23.66% |
| 2010 Q3 | 3.73 Million USD | -0.21% |
| 2010 Q4 | 3.09 Million USD | -17.04% |
| 2010 Q2 | 3.74 Million USD | 1.03% |
| 2010 Q1 | 3.7 Million USD | -8.75% |
| 2010 FY | 14.27 Million USD | 10.24% |
| 2009 Q3 | 3.31 Million USD | 25.73% |
| 2009 Q2 | 2.63 Million USD | -10.37% |
| 2009 Q1 | 2.94 Million USD | -22.53% |
| 2009 FY | 12.94 Million USD | -15.02% |
| 2009 Q4 | 4.05 Million USD | 22.46% |
| 2008 Q1 | 4.33 Million USD | 40.43% |
| 2008 Q4 | 3.79 Million USD | 20.17% |
| 2008 Q3 | 3.15 Million USD | -19.97% |
| 2008 FY | 15.23 Million USD | 29.2% |
| 2008 Q2 | 3.94 Million USD | -8.89% |
| 2007 Q2 | 3.13 Million USD | 25.5% |
| 2007 Q1 | 2.49 Million USD | 135.39% |
| 2007 Q3 | 3.07 Million USD | -2.01% |
| 2007 Q4 | 3.08 Million USD | 0.39% |
| 2007 FY | 11.78 Million USD | 67.01% |
| 2006 Q3 | - USD | 100.0% |
| 2006 FY | 7.05 Million USD | 97.79% |
| 2006 Q2 | -1.49 Million USD | -22.58% |
| 2006 Q1 | -1.21 Million USD | -40.65% |
| 2006 Q4 | -7.05 Million USD | 0.0% |
| 2005 Q4 | -866 Thousand USD | 0.0% |
| 2005 Q2 | -866 Thousand USD | 0.0% |
| 2005 FY | 3.56 Million USD | 227.28% |
| 2005 Q3 | -866 Thousand USD | 0.0% |
| 2005 Q1 | -866 Thousand USD | 0.0% |
| 2004 FY | -2.8 Million USD | -394.23% |
| 2003 FY | 953 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 59.789% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -39.167% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -10.722% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 75.197% |
| Azitra, Inc. | 8.3 Million USD | -55.353% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -44.305% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -87.955% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 55.512% |
| CEL-SCI Corporation | 31.47 Million USD | 59.023% |
| iBio, Inc. | 16.85 Million USD | 23.495% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 60.923% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 36.093% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 48.122% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 7.419% |
| NanoViricides, Inc. | 8.51 Million USD | -51.454% |
| Oragenics, Inc. | 5.45 Million USD | -136.576% |
| BiomX Inc. | 26.81 Million USD | 51.898% |
| BiomX Inc. | 26.81 Million USD | 51.898% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 59.759% |
| Palatin Technologies, Inc. | 34.67 Million USD | 62.798% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 67.606% |